Evidence review demonstrates rising prior authorization denials among US patients seeking branded medications, highlighting growing international challenges to drug access and affordability.
In this update we review new evidence on the rising prevalence of prior authorization rejections, delays and denials affecting US patients seeking access to branded prescription medications. We also examine a comparative study of cost-effectiveness thresholds cited in the USA and in countries designated as comparators under the Most-Favored-Nations Executive Order.
No takes yet. Share an insight, caveat, or question.
Ramagopalan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: